US Phlow Model And Drug Nationalism: Do Indian Firms Need To Be Watchful?
Executive Summary
The new US public benefit pharma manufacturing firm Phlow has received significant federal funding in a bid to improve domestic supply security. Scrip speaks to prominent executives in India's industry over whether this model, if widely replicated, could put at risk the clout and market access plans of the Indian generic industry, a major supplier to the US market.
You may also be interested in...
How Cipla Is Aligning Manufacturing Amid The Pandemic
Cipla senior management executive tells Scrip how the company is calibrating manufacturing as part of a wider business “reimagination” and accelerated digital adoption across its operations.
Civica Rx Partners With Kaiser Permanente
Civica Rx and Kaiser, two non-profit organizations, have announced a partnership to ensure the uninterrupted supply of essential generics to health providers across US during the coronavirus pandemic.
AAM Offers Drug Manufacturing Repatriation Plan … For A Price
Under generic industry group’s proposal, the federal government would have to pay more for drugs to ensure industry investments in domestic manufacturing pay off.